Pharmafile Logo
Pharmafocus logo
Advanced Search

ash

Showing 6 posts of 6 posts found.

Red blood cells

ASH 2015 roundup: Amgen, MorphoSys, Novartis and Roche present new trial data

December 8, 2015
Research and Development Amgen, Cancer, Novartis, Roche, ash, morphosys, oncology

Amgen Amgen presented data from three Phase II trials evaluating Blincyto (blinatumomab) in acute lymphoblastic leukemia (ALL)- a rare and …

News
EMA inside

Sandoz announces biosimilar successes

December 8, 2015
Manufacturing and Production American Society of Hematology, Enbrel, Neulasta, Sandoz, ash, biosimilars, etanercept, pegfilgrastim

Novartis’ biosimilars division Sandoz has announced progress in its biosimilars programme, with its version of Amgen’s Neulasta proving as effective …

News
Ninlaro

Takeda’s Ninlaro extends myeloma survival in trial

December 7, 2015
Manufacturing and Production, Research and Development Ninlaro, Takeda, ash, ixazomib, multiple myeloma

Takeda has presented trial data showing that treatment with its oral proteasome inhibitor Ninlaro extended progression free survival by 35% …

News
ASH 2014 meeting

Bayer and Novartis to debut new data at ASH 2015

November 30, 2015
Research and Development, Sales and Marketing American Society of Hematology, Bayer, Conference, Novartis, ash, clinical trials, haematology, oncology

Pharma firms will present clinical trial results for the pipeline drugs they are pinning their 2016 hopes for success on, …

News
Takeda image

Takeda eyes new drug licences following positive blood cancer studies

December 11, 2014
Research and Development, Sales and Marketing Adcetris, Takeda, Velcade, ash, bortezomib, brentuximab vedotin, hematology

Takeda is bringing its biotech arm in-house to create a global oncology business unit, which it says will drive forward …

News
Boehringer image

Boehringer trials Pradaxa anti-bleeding antidote

December 11, 2014
Sales and Marketing BMS, Bayer, Boehringer, Eliquis, Pradaxa, ash, dabigatran, idarucizumab

Boehringer Ingelheim says that its investigational drug can safely reverse the blood-thinning effect of its anti-clotting drug Pradaxa (dabigatran). The …

News
The Gateway to Local Adoption Series

Latest content

HonorHealth Research Institute announces first patient dosed with new stroke treatment

February 2, 2026

Accord Healthcare appoints Paul Burden as Associate Vice President and Country Head UK

February 2, 2026

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026

Rare diseases – spinal muscular atrophy

January 30, 2026

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026